Experienced in Primitive Neuroectodermal Tumor (PNET)

Dr. Salma K. Jabbour

Radiation Oncology
Rutgers Health-Rwj Scleroderma Program
195 Little Albany St, 
New Brunswick, NJ 
Accepting New Patients
Experienced in Primitive Neuroectodermal Tumor (PNET)
Rutgers Health-Rwj Scleroderma Program
195 Little Albany St, 
New Brunswick, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Salma Jabbour is a Radiation Oncologist in New Brunswick, New Jersey. Dr. Jabbour is rated as an Experienced provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Liver Embolization, and Pancreaticoduodenectomy. Dr. Jabbour is currently accepting new patients.

Her clinical research consists of co-authoring 231 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in NJ
Hospital Affiliations
Robert Wood Johnson University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

RUTGERS HEALTH-RWJ SCLERODERMA PROGRAM
195 Little Albany St, New Brunswick, NJ 08901

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: December 17, 2025
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Moving PD-1 Blockade With Pembrolizumab Into Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
Moving PD-1 Blockade With Pembrolizumab Into Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 16, 2025
Intervention Type: Radiation, Drug, Other, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 1
A Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
A Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Enrollment Status: Suspended
Publish Date: December 05, 2025
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Avelumab, Peposertib
Study Phase: Phase 1/Phase 2
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Enrollment Status: Completed
Publish Date: December 04, 2025
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 2
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: October 10, 2025
Intervention Type: Radiation, Drug
Study Drug: Sorafenib Tosylate
Study Phase: Phase 3
Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer
Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Other, Radiation, Drug
Study Drug: Paclitaxel
Study Phase: Phase 2
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Radiation
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Phase II Study of Preoperative Pembrolizumab for Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer Followed by Chemotherapy and Chemoradiation With Pembrolizumab
A Phase II Study of Preoperative Pembrolizumab for Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer Followed by Chemotherapy and Chemoradiation With Pembrolizumab
Enrollment Status: Active_not_recruiting
Publish Date: April 16, 2025
Intervention Type: Other, Drug, Radiation, Biological
Study Drugs: Capecitabine, Pembrolizumab
Study Phase: Phase 2
Phase II Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081
Phase II Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081
Enrollment Status: Completed
Publish Date: March 11, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
Registry for Proton Beam Radiation Therapy
Registry for Proton Beam Radiation Therapy
Enrollment Status: Completed
Publish Date: July 24, 2023
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Enrollment Status: Unknown
Publish Date: May 24, 2022
Intervention Type: Drug, Procedure, Radiation
Study Drugs: mFOLFIRINOX, FOLFOX
Study Phase: Phase 2
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: August 05, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 2
Sensory Evaluation of a New Oral Nutrition Supplement in Patients at Risk for Mucositis
Sensory Evaluation of a New Oral Nutrition Supplement in Patients at Risk for Mucositis
Enrollment Status: Completed
Publish Date: November 17, 2017
Intervention Type: Dietary supplement, Other
Study Phase: Not Applicable
View 16 Less Clinical Trials

231 Total Publications

Radiation Therapy for Gastric Cancer: An ASTRO Clinical Practice Guideline.
Radiation Therapy for Gastric Cancer: An ASTRO Clinical Practice Guideline.
Journal: Practical radiation oncology
Published: October 06, 2025
Similar Doctors
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Kathryn F. Beal
Radiation Oncology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Kathryn F. Beal
Radiation Oncology

Weill Medical College Of Cornell

525 E 68th St, 
New York, NY 
 (31.9 miles away)
212-746-2971
Languages Spoken:
English, Spanish
Accepting New Patients
Offers Telehealth

Kathryn Beal is a Radiation Oncologist in New York, New York. Dr. Beal is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, Metastatic Brain Tumor, and Oligodendroglioma. Dr. Beal is currently accepting new patients.

Anuj Goenka
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Anuj Goenka
Radiation Oncology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Anuj Goenka
Radiation Oncology

Northwell Health Cancer Institute Radiation Medicine At The Center For Advanced Medicine

450 Lakeville Road, Entrance A, 
Lake Success, NY 
 (43.1 miles away)
855-927-6622
Languages Spoken:
English, Hindi
See accepted insurances
Offers Telehealth

Anuj Goenka is a Radiation Oncologist in Lake Success, New York. Dr. Goenka is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). His top areas of expertise are Oligodendroglioma, Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, Gamma Knife Radiosurgery, and Gastrostomy.

Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Goldie A. Kurtz
Radiation Oncology
Distinguished in Primitive Neuroectodermal Tumor (PNET)
Dr. Goldie A. Kurtz
Radiation Oncology

Penn Radiation Oncology Perelman - 2nd Floor

3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 
 (54.6 miles away)
800-789-7366
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Goldie Kurtz is a Radiation Oncologist in Philadelphia, Pennsylvania. Dr. Kurtz has been practicing medicine for over 17 years and is rated as a Distinguished provider by MediFind in the treatment of Primitive Neuroectodermal Tumor (PNET). Her top areas of expertise are Metastatic Brain Tumor, Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), and Meningioma. Dr. Kurtz is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jabbour's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 11 Advanced Conditions
View All 41 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile